Real-life Experience in Brazil in Patients With Castration-resistant Prostate Cancer Treated With Olaparib+Abiraterone
Reason given: 1. Decentralized sites. 2. Lack of sites interest in the study. 3. Super estimate of potential patient numbers. 4. Transforming the protocol to a retrospective one could impact the study's publication timeline.
Key facts
- Where
- Natal, Salvador, Santa Maria, and São Paulo, BrazilSee the 5 sites
Where in Brazil
- Liga Norte-Rio-Grandense Contra o CâncerNatal, BrazilNo longer taking part
- Clinica AMOSalvador, BrazilNo longer taking part
- Clinica ViverSanta Maria, BrazilNo longer taking part
- Hospital Albert EinsteinSão Paulo, BrazilNo longer taking part
- Hospital Alemão Oswaldo CruzSão Paulo, BrazilNo longer taking part
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT06457854
- Record updated
- 12 March 2025
- Original description
PROCeed is an observational study assessing real world clinical endpoints and demographic characteristics in patients with castration-resistant prostate cancer treated with Olaparib+Abiraterone.Read full original descriptionShow less
Real-life Experience in Brazil in Patients With Castration-resistant Prostate Cancer Treated With Olaparib+Abiraterone Observational Study Assessing Real World Clinical Endpoints and Demographic Characteristics in Patients With Castration-resistant Prostate Cancer Treated With Olaparib+Abiraterone
PROCeed is an observational study assessing real world clinical endpoints and demographic characteristics in patients with castration-resistant prostate cancer treated with Olaparib+Abiraterone.
Inclusion: Willing to provide written informed consent; 18 years or older; Documented histology or cytology of PCa, adenocarcinoma; Documented as mCRPC; Olaparib+abiraterone started after the activation of the research site.
Exclusion: Patients participating in a clinical trial with investigational treatment for prostate cancer within 30 days before starting olaparib.